Testosterone Levels in People Taking Regular Low-Dose Sustained-Release Morphine for Persisting Breathlessness: An Exploratory Study.

Ferreira, DH; Ekström, M; Fazekas, B; Currow, DC

Testosterone Levels in People Taking Regular Low-Dose Sustained-Release Morphine for Persisting Breathlessness: An Exploratory Study.

Ferreira, DH Ekström, M Fazekas, B Currow, DC

Permalink

Publisher:: MARY ANN LIEBERT, INC
Publication Type:: Journal Article
Citation:: J Palliat Med, 2023, 26, (3), pp. 402-405
Issue Date:: 2023-03

Closed Access

	Filename	Description	Size
	jpm.2022.0381.pdf		159.2 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Ferreira, DH
dc.contributor.author	Ekström, M
dc.contributor.author	Fazekas, B
dc.contributor.author	Currow, DC
dc.date.accessioned	2023-09-21T04:35:23Z
dc.date.available	2023-09-21T04:35:23Z
dc.date.issued	2023-03
dc.identifier.citation	J Palliat Med, 2023, 26, (3), pp. 402-405
dc.identifier.issn	1096-6218
dc.identifier.issn	1557-7740
dc.identifier.uri	http://hdl.handle.net/10453/172233
dc.description.abstract	Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All three had worsening illness at the time of the second assessment. There was no apparent relationship between change in testosterone, morphine dose, and change in breathlessness. Conclusions: Substantial declines in testosterone were uncommon and were not apparently related to changes in morphine dose or breathlessness, but they were possibly related with worsening illness.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	MARY ANN LIEBERT, INC
dc.relation	http://purl.org/au-research/grants/nhmrc/1065571
dc.relation.ispartof	J Palliat Med
dc.relation.isbasedon	10.1089/jpm.2022.0381
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1110 Nursing, 1117 Public Health and Health Services
dc.subject.classification	Gerontology
dc.subject.classification	4203 Health services and systems
dc.subject.classification	4205 Nursing
dc.subject.mesh	Male
dc.subject.mesh	Humans
dc.subject.mesh	Morphine
dc.subject.mesh	Delayed-Action Preparations
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Dyspnea
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Testosterone
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Humans
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Dyspnea
dc.subject.mesh	Morphine
dc.subject.mesh	Testosterone
dc.subject.mesh	Analgesics, Opioid
dc.subject.mesh	Delayed-Action Preparations
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Male
dc.subject.mesh	Male
dc.subject.mesh	Humans
dc.subject.mesh	Morphine
dc.subject.mesh	Delayed-Action Preparations
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Dyspnea
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Testosterone
dc.subject.mesh	Analgesics, Opioid
dc.title	Testosterone Levels in People Taking Regular Low-Dose Sustained-Release Morphine for Persisting Breathlessness: An Exploratory Study.
dc.type	Journal Article
utslib.citation.volume	26
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1110 Nursing
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
dc.date.updated	2023-09-21T04:35:21Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	26
utslib.citation.issue	3

Abstract:

Background: The intermediate- and long-term effects of regular low-dose sustained-release (SR) morphine on the testosterone levels of people with persistent breathlessness are unknown. Methods: Exploratory analysis of a randomized controlled trial of the effects of regular SR morphine (0/8/16/24 mg every 24 hours) for persistent breathlessness associated with chronic obstructive pulmonary disease. Total testosterone was measured at baseline and at cessation (greater than or equal to three months on stable medication). Results: Among 20 participants (9 males; median treatment duration between measurements 169 days [IQR 162-175]), only 3 had substantial declines in testosterone levels during the study (morphine 8, 16, 24 mg groups). All three had worsening illness at the time of the second assessment. There was no apparent relationship between change in testosterone, morphine dose, and change in breathlessness. Conclusions: Substantial declines in testosterone were uncommon and were not apparently related to changes in morphine dose or breathlessness, but they were possibly related with worsening illness.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/172233